Highview Capital Management LLC DE Has $1.84 Million Holdings in Boston Scientific Corporation $BSX

Highview Capital Management LLC DE trimmed its stake in Boston Scientific Corporation (NYSE:BSX) by 32.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,122 shares of the medical equipment provider’s stock after selling 8,369 shares during the quarter. Highview Capital Management LLC DE’s holdings in Boston Scientific were worth $1,839,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BSX. Brighton Jones LLC grew its holdings in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares in the last quarter. Kingsview Wealth Management LLC grew its stake in Boston Scientific by 2.6% in the first quarter. Kingsview Wealth Management LLC now owns 6,735 shares of the medical equipment provider’s stock valued at $679,000 after purchasing an additional 172 shares in the last quarter. Private Advisor Group LLC raised its stake in shares of Boston Scientific by 10.8% during the 1st quarter. Private Advisor Group LLC now owns 38,274 shares of the medical equipment provider’s stock worth $3,861,000 after purchasing an additional 3,734 shares in the last quarter. IFP Advisors Inc lifted its holdings in shares of Boston Scientific by 105.7% during the 1st quarter. IFP Advisors Inc now owns 16,675 shares of the medical equipment provider’s stock valued at $1,682,000 after buying an additional 8,570 shares during the last quarter. Finally, Montag A & Associates Inc. grew its stake in shares of Boston Scientific by 31.4% in the 1st quarter. Montag A & Associates Inc. now owns 3,286 shares of the medical equipment provider’s stock valued at $331,000 after buying an additional 786 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares in the company, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 175,782 shares of company stock worth $17,742,314 in the last three months. Insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 2.5%

BSX opened at $99.23 on Wednesday. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50. The business has a 50 day moving average of $99.41 and a 200-day moving average of $102.51. The stock has a market capitalization of $147.10 billion, a price-to-earnings ratio of 53.06, a P/E/G ratio of 2.02 and a beta of 0.58. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same period in the prior year, the firm earned $0.63 EPS. The business’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on BSX. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Morgan Stanley boosted their price target on Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Evercore ISI reiterated an “outperform” rating on shares of Boston Scientific in a research note on Wednesday, October 22nd. Robert W. Baird raised their price objective on Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Finally, Barclays increased their price target on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $123.77.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.